As per the new report from the Cell and Gene Therapy Catapult (CGT Catapult) showed there is a growth in the employment for cell and gene therapy sectors. A report showing that the industry currently offers over 3,000 jobs, with 1,700 roles in manufacturing and bioprocessing.
By 2024, the UK is expected to double the employment in the cell and gene sector because more treatments are moving towards commercialization. This clearly proves that in the last seven years, the sector has reached from 500 jobs in 2012 to over 3,000, and is expected to reach over 6,000 jobs by 2024.
Good Manufacturing Practice (GMP) manufacturing report, in addition to its skills, demand report, shows that in addition to the employment figures, the manufacturing sector in academia and industry is also growing for the fifth consecutive year, with facilities rapidly becoming operational. Manufacturing capacity specifically in the UK is due to increase even further in 2020 – principally from Oxford Biomedica and the expansion of the CGT Catapult.
Keith Thompson, the catapult’s chief executive officer also said the progress has been hailed as “encouraging”. He also said that the advanced treatments are progressing from research into becoming business commercial products. Continuous support from Innovate UK and UK Research and Innovation, sector have been able to accelerate the growth of the UK ecosystem, the infrastructures and the systems that can enable businesses to grow and for their treatments to reach patients.
He also expressed that the industry is in need of many more skilled people to keep growing and the expansion of programs such as the Advanced Therapies Apprenticeship Community (ATAC) is an essential part of this.